Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SPM 907 · 5 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| SPM 907 | DRUG | - |
Inclusion Criteria: * Participated in SP583 Exclusion Criteria: * Failure to complete 12 week treatment with SPM 907
SPM 907 is an investigational small molecule being developed for the treatment of Overactive Bladder Syndrome and Overactive Bladder. It is currently in Phase 3 clinical development, though all listed trials have been completed.
SPM 907 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials for this drug in the therapeutic area of nephrology.
SPM 907 is in Phase 3 clinical development for Overactive Bladder Syndrome and Overactive Bladder. It is an investigational drug, meaning it has not been approved by regulatory authorities and remains under clinical investigation.
SPM 907 has been studied in completed clinical trials including NCT00220363, a Phase 3 trial in Germany for Overactive Bladder Syndrome, and NCT00220376, a long-term open-label extension trial in the United States. Additional trials NCT00220389 and NCT00220402 are also completed.
SPM 907 is associated with fesoterodine sustained release formulations in clinical trials. The trials listed for SPM 907 investigate fesoterodine sustained release for Overactive Bladder Syndrome, indicating SPM 907 may be an alternative name for this drug.